International Financial Reporting Standards (IFRS) Financial and Non-Financial Highlights Chugai Pharmaceutical Co., Ltd. and Consolidated Subsidiaries/Years ended December 31 Financial Indicators (Core Basis) Results Ratio of cost of sales to sales (%) Ratio of operating expenses to revenues (%) Japanese GAAP IFRS (Core basis) 46.0 46.4 45.4 44.6 43.2 43.1 37.2 37.2 39.5 39.8 40.2 35.8 390.2 Sales (excluding Tamiflu) 357.4 354.7 363.2 (Billions of yen) 342.9 61.1 33.0 9.2% 42.3 11.6% 15.7% 313.4 33.6 9.8% 39.7 11.2% 37.4 30.1 8.3% 28.6 7.3% Overseas 33.5 10.7% 40.9 10.5% 33.7 9.5% 18.8 4.8% 11.9% 25.8 7.2% 20.3 5.6% Others 22.8 6.4% 42.3 13.5% 26.2 7.6% 48.1 48.9 12.5% Transplant, immunology 57.4 50.6 13.2% 24.0 7.7% 16.1% 14.3% and infectious diseases 61.0 60.6 61.3 17.8% 66.3 15.5% Renal diseases 62.6 66.1 18.3% 19.6% 17.5% 18.6% Bone and joint 57.6 16.8% diseases 50.0 16.0% 172.4 141.2 141.8 156.1 Oncology 102.3 123.7 32.6% 36.1% 39.5% 40.0% 43.0% 44.2% 2008 2009 2010 2011 2012 2013 Business process reengineering Budget control Launch of main products in Japan Actemra Edirol Perjeta (rheumatoid arthritis) Mircera Actemra (subcutaneous injection) Bonviva Approval of main products overseas Actemra Actemra Actemra (rheumatoid (rheumatoid (subcutaneous arthritis, E.U.) arthritis, U.S.) injection, U.S.) Chugai product Revenues/ Operating Profit/ Net Income/Core EPS Royalties and Other Operating Income Ratio of Operating Profit to Revenues (Billions of yen/Yen) (Billions of yen) (Billions of yen/%) 76.7 534.2 541.5 103.2 108.0 498.8 491.8 461.1 90.7 64.9 80.6 56.8 147.00 77.3 53.0 19.3 116.42 138.68 18.2 19.9 102.50 43.0 16.8 16.4 95.04 30.4 34.9 24.2 19.1 2014 2015 2016 2017 2018 2014 20152016 2017 2018 2014 2015 2016 2017 2018 (Forecast) (Forecast) (Forecast) Revenues Operating profit Net income Royalties and other operating income Ratio of operating profit to revenues Core EPS Revenues continue to expand, led by increases Chugai’s ratio of operating profit to revenues In mid-term business plan IBI 18, we set a Core in exports of Chugai products and in royalties is consistently high due to the low ratio of EPS compound annual growth rate (CAGR) of and other operating income (ROOI). ROOI is operating expenses to revenues. In 2017, the less than 4 percent as the quantitative outlook, composed of recurring income, which has been increase in ROOI and the higher percentage of with 2015 as the baseline, and are using it as a increasing in conjunction with overseas sales of Chugai products in the sales mix resulted in a key performance indicator shared both internally Actemra, and non-recurring income, which lower ratio of cost of sales to sales, which and externally. In the forecast for 2018, we changes from year to year and is the principal contributed to the increase in the ratio of project that this indicator will be 9.5 percent,1 factor in the fluctuations in ROOI. operating profit to revenues. In 2018, we expect significantly higher than our original plan. record profit for a second consecutive year due to growth of mainstay products and ROOI. 1. Based on average exchange rates for 2015 12 CHUGAI PHARMACEUTICAL CO., LTD. Chugai has substantially improved its cost structure in view of the rising cost of sales 51.0 52.2 49.7 50.7 50.6 to sales ratio resulting from the increase in products in-licensed from Roche under the strategic alliance between the two companies. We have now secured high 36.2 33.9 33.4 33.3 33.5 profitability by continuously achieving a ratio of operating expenses to revenues at a level 482.4 492.9 that compares favorably with the world’s 459.2 460.2 leading pharmaceutical companies. 423.8 94.0 118.1 82.2 79.5 19.5% Sales have grown steadily in the area of 74.3 17.9% 17.3% 24.0% 18.5 4.0% 6.2% 2 17.5% 21.7 4.7% 29.9 27.9 5.7% oncology based on products in-licensed from 15.9 3.5% 13.7 3.0% 25.6 6.0% 41.1 39.3 8.1% 35.3 7.2% Roche as well as Alecensa, a product from 20.8 4.9% 45.4 9.9% 9.0% Chugai’s research. Sales also continue to grow 44.7 10.5% 93.3 79.4 86.1 97.1 in the area of bone and joint diseases, driven 18.8% 19.3% 69.6 17.3% 19.7% 16.4% by Chugai products Edirol and Actemra, the first therapeutic antibody created in Japan. 215.7 220.3 225.9 214.5 188.9 2. Sales of the transplant, immunology and infectious diseases area, which were disclosed separately up until 2016, were included and disclosed in sales of the Others area from 2017. 44.6% 46.9% 48.0% 46.8% 43.5% 2014 2015 2016 2017 2018 (Forecast) Productivity improvement Kadcyla Zelboraf Alaglio Alecensa Actemra Alecensa (U.S.) Hemlibra (U.S., E.U.) （subcutaneous Alecensa (E.U.) injection, E.U.) Exports to Roche/Overseas Sales Ratio Dividends per Share/Core Payout Ratio (Billions of yen/%) (Yen/%) About Core Basis Results Chugai reports its results on a Core 99.6 basis from 2013 in conjunction with 62 62 58 its decision to adopt IFRS. Core 76.4 6 52 48 basis results are the IFRS basis 63.1 62.8 results adjusted by excluding non- 55.1 26.1 49.8 50.7 21.8 44.7 Core items, and are consistent with 23.1 50.5 42.2 19.1 19.6 the concept of Core basis results disclosed by Roche. Core basis results are used by Chugai as internal performance indicators for 2014 20152016 2017 2018 2014 2015 2016 2017 2018 (Forecast) (Forecast) representing recurring profit trends Exports to Roche Annual dividends per share both internally and externally, and Overseas sales ratio Special dividends Core payout ratio (Core EPS basis) as indices for establishing profit distributions such as returns to Chugai product Actemra has grown into a Regarding shareholder returns, we target stable shareholders. No items have been mainstay product of the Roche Group, with dividends with a Core EPS payout ratio of 50 excluded from the IFRS balance global sales (including Japan) surpassing 1.9 percent on average, based on an approach of sheet and cash flows, as the Core billion Swiss francs in 2017. Alecensa, another dividing core net income equally between the basis results concept only applies product from Chugai research, received approval Company and our shareholders. This policy will to the income statement. in Europe and the United States for the continue unchanged under IBI 18, our current additional indication of first-line treatment at mid-term business plan. the end of 2017, and is expected to drive overseas sales. ANNUAL REPORT 2017 13 Research, Clinical Development and Production R&D Expenditures/R&D Expenditures to Revenues/Pipeline Projects R&D expenditures (Billions of yen)R&D expenditures to revenues (%) Number of pipeline projects 88.9 Japanese GAAP IFRS (Core basis) 40 82.6 80.6 81.9 41 37 74.1 39 34 34 70.5 34 66.6 34 30 55.3 53.2 54.7 28 18.9 17.5 17.2 17.5 16.4 16.8 16.3 16.6 12.9 14.4 20082009 2010 2011 2012 2013 2014 2015 2016 2017 Participation in multinational studies Approval and Development of proprietary antibody CPR establishment and business expansion, development engineering technologies out-licensing of Chugai products of Actemra Investment in facilities to handle multiple development projects simultaneously As revenues grow, Chugai increases investment in research and development. Under our strategic alliance with Roche, we have been promoting new drug In addition to the steady creation of innovative drugs, this leads to research development with higher success rates and greater efficiency by collaborating findings that may contribute to the advancement of healthcare and the with Roche in ways such as examining and deciding on which Roche products pharmaceutical industry worldwide. Our policy is to proactively conduct to in-license based on the results of early-stage clinical trials. In recent years, speedy research and development in light of the competitive environment, we have maintained a robust pipeline, with numerous products from Chugai as well as upfront investment to acquire and enhance future competitiveness, research having moved into the clinical phase, including in-house products while keeping growth in overall operating expenses within the rate of revenue from Chugai Pharmabody Research (CPR),1 which has expanded its operations growth as a general principle. to accelerate the creation of innovative therapeutic antibodies. 1. Established in Singapore in 2012 Publications in Academic Papers and New Products Launched and Energy Consumption/ Presentations at Scientific Conferences New Indications/Percentage of Product Energy Consumption per Employee 2 regarding Chugai Research Findings Sales Qualifying for Premium Pricing (Thousands of GJ/GJ per employee) (Number/%) 95 2,384 87 86 78 78 2,184 2,211 2,170 2,185 84 75 73 74 74 5 355 311 308 299 296 3 2 2 2 2013 2014 2015 2016 2017 2013 2014 2015 2016 2017 20103 2014 2015 2016 2017 New products launched and new indications Energy consumption Percentage of product sales qualifying for Energy consumption per employee premium pricing Chugai develops innovative medicines that allow Products that qualify for premium pricing As it expands its production system for new it to differentiate itself from competitors by account for a consistently high proportion of drugs by introducing facilities, Chugai is continuously establishing proprietary drug Chugai’s sales.